Heparan sulfate–binding sites on viral proteins

Heparan sulfate–binding sites on viral proteins are critical structural domains located on the surface of many enveloped and non-enveloped viruses, including SARS-CoV-2, Herpes Simplex Virus (HSV), and Human Immunodeficiency Virus (HIV) (mdpi.com, nih.gov). These sites facilitate the initial attachment of the virus to host cells by interacting electrostatically with negatively charged heparan sulfate proteoglycans (HSPGs) on the cell membrane (mdpi.com, glycoforum.gr.jp). This interaction serves to concentrate viral particles at the cell surface, often triggering conformational changes that allow the virus to engage more specific entry receptors (nih.gov, mdpi.com). Because this mechanism is conserved across diverse viral families, these binding sites are attractive targets for broad-spectrum antiviral therapies (researchgate.net, nih.gov). Therapeutic strategies include the use of heparan sulfate mimetics, such as heparin, pixatimod, and suramin, which act as competitive inhibitors or decoy receptors to block viral docking (mdpi.com, nih.gov). However, challenges such as the anticoagulant properties of heparin-like molecules and the need for high specificity to avoid interfering with host HS-dependent signaling must be addressed in drug development (acs.org, mdpi.com).

Other names

Viral attachment proteinsHSPG-binding domainsGlycosaminoglycan-binding sitesHeparan sulfate-binding domainsHSBDsViral GAG-binding sites

Competitive inhibition of viral attachment to host cell surface heparan sulfate proteoglycans (HSPGs) by acting as a decoy receptor or masking the viral binding site.